$3.2M
+$3.2M this year1 filing since 2026 · latest Equity filed
Goldenrod Therapeutics is a Houston-based, Fannin-founded biotech developing brain-penetrant, next-generation phosphodiesterase 4 (PDE4) inhibitors for neurological disorders. Its lead small-molecule candidate, 11h, was developed at the University of Nebraska Medical Center and targets neuroinflammation, with Friedreich's ataxia as the first indication. In 2026 it closed the first tranche of a $6.5M Series Seed led by Ataxia Ventures and a Fannin Partners affiliate to fund IND-enabling work and a Phase I study.
What sets it apart
Brain-optimized, selective PDE4 inhibitors engineered for high CNS exposure and better tolerability than earlier PDE4 drugs.
A brain-penetrant small-molecule PDE4 inhibitor targeting neuroinflammation and neuronal signaling, headed toward a Phase I study with Friedreich's ataxia as the lead indication.
